Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance

Voges, Yvonne and Michaelis, Martin and Rothweiler, Florian and Schaller, Torsten and Schneider, Constanze and Politt, Katharina and Mernberger, Marco and Nist, Andrea and Stiewe, Thorsten and Wass, Mark N. and Rödel, Franz and Cinatl, Jindrich (2016) Effects of YM155 on survivin levels and viability in neuroblastoma cells with acquired drug resistance. Cell death & disease, 7 (10). e2410. ISSN 2041-4889. (doi:https://doi.org/10.1038/cddis.2016.257) (Full text available)

PDF - Publisher pdf

Creative Commons Licence
This work is licensed under a Creative Commons Attribution 4.0 International License.
Download (1MB) Preview
[img]
Preview
Official URL
http://dx.doi.org/10.1038/cddis.2016.257

Abstract

Resistance formation after initial therapy response (acquired resistance) is common in high-risk neuroblastoma patients. YM155 is a drug candidate that was introduced as a survivin suppressant. This mechanism was later challenged, and DNA damage induction and Mcl-1 depletion were suggested instead. Here we investigated the efficacy and mechanism of action of YM155 in neuroblastoma cells with acquired drug resistance. The efficacy of YM155 was determined in neuroblastoma cell lines and their sublines with acquired resistance to clinically relevant drugs. Survivin levels, Mcl-1 levels, and DNA damage formation were determined in response to YM155. RNAi-mediated depletion of survivin, Mcl-1, and p53 was performed to investigate their roles during YM155 treatment. Clinical YM155 concentrations affected the viability of drug-resistant neuroblastoma cells through survivin depletion and p53 activation. MDM2 inhibitor-induced p53 activation further enhanced YM155 activity. Loss of p53 function generally affected anti-neuroblastoma approaches targeting survivin. Upregulation of ABCB1 (causes YM155 efflux) and downregulation of SLC35F2 (causes YM155 uptake) mediated YM155-specific resistance. YM155-adapted cells displayed increased ABCB1 levels, decreased SLC35F2 levels, and a p53 mutation. YM155-adapted neuroblastoma cells were also characterized by decreased sensitivity to RNAi-mediated survivin depletion, further confirming survivin as a critical YM155 target in neuroblastoma. In conclusion, YM155 targets survivin in neuroblastoma. Furthermore, survivin is a promising therapeutic target for p53 wild-type neuroblastomas after resistance acquisition (neuroblastomas are rarely p53-mutated), potentially in combination with p53 activators. In addition, we show that the adaptation of cancer cells to molecular-targeted anticancer drugs is an effective strategy to elucidate a drug's mechanism of action.

Item Type: Article
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Martin Michaelis
Date Deposited: 15 Oct 2016 13:22 UTC
Last Modified: 08 Jun 2017 08:50 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/57888 (The current URI for this page, for reference purposes)
Michaelis, Martin: https://orcid.org/0000-0002-5710-5888
Wass, Mark N.: https://orcid.org/0000-0001-5428-6479
  • Depositors only (login required):

Downloads

Downloads per month over past year